These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 8750250)

  • 21. Implications of 4S evidence on baseline lipid levels.
    Jacobson TA
    Lancet; 1995 Jul; 346(8968):181-2. PubMed ID: 7603245
    [No Abstract]   [Full Text] [Related]  

  • 22. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prevention and therapy of vascular damage and endothelial dysfunction with hypocholesteremic agents].
    De Caterina R; Lenzi S
    G Ital Cardiol; 1998 Feb; 28(2):168-77. PubMed ID: 9534058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
    Schiel R; Bambauer R; Müller UA
    Int J Artif Organs; 1995 Dec; 18(12):786-93. PubMed ID: 8964646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [LDL cholesterol in normal range. The lower the better? Implications of the GREACE study].
    März W
    MMW Fortschr Med; 2003 Dec; 145(50):46-9. PubMed ID: 14963971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging.
    Corti R; Fuster V; Fayad ZA; Worthley SG; Helft G; Smith D; Weinberger J; Wentzel J; Mizsei G; Mercuri M; Badimon JJ
    Circulation; 2002 Dec; 106(23):2884-7. PubMed ID: 12460866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease.
    Haffner SM
    Diabetes Care; 1997 Apr; 20(4):469-71. PubMed ID: 9096961
    [No Abstract]   [Full Text] [Related]  

  • 28. Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: a mechanism for reducing clinical events?
    Cohen JD; Drury JH; Ostdiek J; Finn J; Babu BR; Flaker G; Belew K; Donohue T; Labovitz A
    Am Heart J; 2000 Apr; 139(4):734-8. PubMed ID: 10740160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implications of 4S evidence on baseline lipid levels.
    Durrington PN
    Lancet; 1995 Jul; 346(8968):181. PubMed ID: 7661979
    [No Abstract]   [Full Text] [Related]  

  • 30. Risk factor modification: rationale for management of dyslipidemia.
    Gotto AM
    Am J Med; 1998 Feb; 104(2A):6S-8S. PubMed ID: 9550500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy.
    Hunninghake DB
    Am J Med; 1998 Feb; 104(2A):9S-13S. PubMed ID: 9550501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of lipid levels and lipid-lowering therapy on restenosis after coronary artery stenting.
    Lerakis S; El-Chami MF; Patel AD; Veledar E; Alexopoulos E; Zacharoulis A; Triantafyllou A
    Am J Med Sci; 2006 May; 331(5):270-3. PubMed ID: 16702797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Making the most of cholesterol-lowering margarines.
    Avery JK
    Cleve Clin J Med; 2001 Mar; 68(3):194-6. PubMed ID: 11263847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Optimal lipid lowering therapy for coronary heart diseases patients in secondary prevention: moderate or aggressive LDL decrease preferred?].
    MMW Fortschr Med; 2006 Nov; 148(48):54-5. PubMed ID: 17615773
    [No Abstract]   [Full Text] [Related]  

  • 35. Aggressive lipid therapy in the statin era.
    Farmer JA
    Prog Cardiovasc Dis; 1998; 41(2):71-94. PubMed ID: 9790411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Critical evaluation of indications for lipid reduction. Cholesterol value updated--risk counts (interview by Dr. Kirsten Westphal)].
    Motz W
    MMW Fortschr Med; 2003 Oct; 145(41):48. PubMed ID: 14655487
    [No Abstract]   [Full Text] [Related]  

  • 37. Updated guidelines support even lower cholesterol levels for at-risk patients.
    Levenson D
    Rep Med Guidel Outcomes Res; 2004 Aug; 15(15):1, 6-7. PubMed ID: 15320342
    [No Abstract]   [Full Text] [Related]  

  • 38. Underutilization of lipid-lowering therapy in coronary artery disease.
    Batalla A; Hevia S; Reguero JR; Cubero GI
    Arch Intern Med; 2000 Sep; 160(17):2683-4. PubMed ID: 10999994
    [No Abstract]   [Full Text] [Related]  

  • 39. Achieving optimal lipid goals in patients with coronary artery disease.
    Karalis DG; Subramanya RD; Hessen SE; Liu L; Victor MF
    Am J Cardiol; 2011 Mar; 107(6):886-90. PubMed ID: 21247526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients].
    Tachibana E; Watanabe I; Nagao K; Kanmatsuse K
    J Cardiol; 2000 Apr; 35(4):277-85. PubMed ID: 10791271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.